Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake

被引:48
|
作者
McKay, Naomi J. [1 ]
Kanoski, Scott E. [2 ]
Hayes, Matthew R. [2 ,3 ]
Daniels, Derek [1 ]
机构
[1] SUNY Buffalo, Dept Psychol, Behav Neurosci Program, Buffalo, NY 14260 USA
[2] Univ Penn, Dept Psychol, Sch Arts & Sci, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychiat, Translat Neurosci Program, Perelman Sch Med, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
exendin-4; liraglutide; hypodipsia; thirst; INCRETIN-BASED THERAPIES; BODY-WEIGHT; BLOOD-PRESSURE; 7-36; AMIDE; INSULIN-SECRETION; CENTRAL INFUSION; GLP-1; RECEPTORS; MESSENGER-RNAS; HEART-RATE; RAT;
D O I
10.1152/ajpregu.00472.2011
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
McKay NJ, Kanoski SE, Hayes MR, Daniels D. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol 301: R1755-R1764, 2011. First published October 5, 2011; doi:10.1152/ajpregu.00472.2011.Glucagon-like peptide-1 (GLP-1) is produced by and released from the small intestine following ingestion of nutrients. GLP-1 receptor (GLP-1R) agonists applied peripherally or centrally decrease food intake and increase glucose-stimulated insulin secretion. These effects make the GLP-1 system an attractive target for the treatment of type 2 diabetes mellitus and obesity. In addition to these more frequently studied effects of GLP-1R stimulation, previous reports indicate that GLP-1R agonists suppress water intake. The present experiments were designed to provide greater temporal resolution and site specificity for the effect of GLP-1 and the long-acting GLP-1R agonists, exendin-4 and liraglutide, on unstimulated water intake when food was and was not available. All three GLP-1R ligands suppressed water intake after peripheral intraperitoneal administration, both in the presence of and the absence of food; however, the magnitude and time frame of water intake suppression varied by drug. GLP-1 had an immediate, but transient, hypodipsic effect when administered peripherally, whereas the water intake suppression by IP exendin-4 and liraglutide was much more persistent. Additionally, intracerebroventricular administration of GLP-1R agonists suppressed water intake when food was absent, but the suppression of intake showed modest differences depending on whether the drug was administered to the lateral or fourth ventricle. To the best of our knowledge, this is the first demonstration of GLP-1 receptor agonists affecting unstimulated, overnight intake in the absence of food, the first test for antidipsogenic effects of hindbrain application of GLP-1 receptor agonists, and the first test of a central effect (forebrain or hindbrain) of liraglutide on water intake. Overall, these results show that GLP-1R agonists have a hypodipsic effect that is independent of GLP-1R-mediated effects on food intake, and this occurs, in part, through central nervous system GLP-1R activation.
引用
收藏
页码:R1755 / R1764
页数:10
相关论文
共 50 条
  • [31] NEPHROPROTECTIVE POTENTIAL OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
    Shamhalova, Minara S.
    Sklyanik, Igor A.
    Shestakova, Marina V.
    DIABETES MELLITUS, 2020, 23 (01): : 56 - 64
  • [32] Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity
    Jensterle, Mojca
    Janez, Andrej
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 599 - 608
  • [33] Weighing in on glucagon-like peptide-1 receptor agonists in dermatology
    Heymann, Warren R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (01) : 29 - 30
  • [34] Glucagon-like peptide-1 receptor agonists in neoplastic diseases
    Ji, Lisan
    He, Xianzhen
    Min, Xinwen
    Yang, Handong
    Wu, Wenwen
    Xu, Hao
    Chen, Jun
    Mei, Aihua
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [35] Renal protection with glucagon-like peptide-1 receptor agonists
    Vitale, Martina
    Haxhi, Jonida
    Cirrito, Tiziana
    Pugliese, Giuseppe
    CURRENT OPINION IN PHARMACOLOGY, 2020, 54 : 91 - 101
  • [36] Clinical pharmacology of glucagon-like peptide-1 receptor agonists
    Sfairopoulos, Dimitrios
    Liatis, Stavros
    Tigas, Stelios
    Liberopoulos, Evangelos
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 17 (03): : 333 - 350
  • [37] UTILIZATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CANADA
    Vannabouathong, C.
    Le, K.
    Dyrda, P.
    VALUE IN HEALTH, 2023, 26 (06) : S217 - S217
  • [38] Clinical pharmacology of glucagon-like peptide-1 receptor agonists
    Dimitrios Sfairopoulos
    Stavros Liatis
    Stelios Tigas
    Evangelos Liberopoulos
    Hormones, 2018, 17 : 333 - 350
  • [39] Glucagon-like peptide-1 receptor agonists and aspiration risk
    McIsaac, Daniel I.
    Bryson, Gregory L.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
  • [40] The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
    Fang, Haowen
    Niu, Bing
    Chen, Qin
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2921 - 2943